Jiangxi Institute of Biological Products Seeks Up to HK$473 Million in Hong Kong IPO
Jiangxi Institute of Biological Products (HKG:6915) launched its Hong Kong initial public offering on Monday, seeking to raise up to HK$473.2 million.The Chinese antiserum company is offering 36.2 million H-shares at an indicative price range of HK$9.33 to HK$13.06 per share, according to a Hong Kong bourse filing.The offering comprises 3.62 million shares for Hong Kong investors and 32.61 million shares for international investors, subject to reallocation and the overallotment option.The offer price is expected to be determined by June 26, with allocation results due by June 29, ahead of the company's planned trading debut on June 30.Net proceeds will be used to expand the company's production and research and development capabilities.The company secured one cornerstone investor who committed to purchasing HK$50 million worth of IPO shares.China International Capital Corp., China Merchants Securities, Futu Securities International, Guosen Securities, CMBC Securities, and Arta Asset Management are serving as the underwriters for the offering.
